Results 171 to 180 of about 5,138,607 (284)

The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose. [PDF]

Osteoporos Int
Konstantelos N, Kim S, Cheung AM, Burden AM, Grootendorst P, Cadarette SM.   +5 more
europepmc   +1 more source

Retraction: Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Efficacy and Safety of Percutaneous Kyphoplasty Combined With Zoledronic Acid for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Tayyab M, Ahmad M, Akbar R, Syed R, Ullah KI, Haq NU, Khan I, Khan AA, Khan A, Javaid MH.   +9 more
europepmc   +1 more source

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

New England Journal of Medicine, 2007
D. Black, P. Delmas, R. Eastell, I. Reid, S. Boonen, J. Cauley, F. Cosman, P. Lakatos, P. Leung, Z. Man, C. Mautalen, P. Mesenbrink, Huilin Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T. Hue, D. Sellmeyer, E. Eriksen, S. Cummings   +20 more
semanticscholar   +1 more source

Evaluate the renal system damage caused by zoledronic acid: A comprehensive analysis of adverse events from FAERS [PDF]

Zhaojun Wang, Xin Su, Donglei Shi, Wěi Li   +3 more
openalex   +1 more source

The Mitigating Effect and Mechanism of Polydeoxyribonucleotide Against Zoledronic Acid-Induced Growth Suppression of Human Gingival Fibroblasts. [PDF]

Int J Mol Sci
Pachhapure S, Shin YM, Kim DG, Choi DR, Yun JI, Kim JH, Jang BC.   +6 more
europepmc   +1 more source

Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors. [PDF]

In Vivo
Watanabe M, Tsuchie H, Nagasawa H, Hongo M, Kasukawa Y, Kudo D, Kasama F, Oya K, Kawaragi T, Miyakoshi N.   +9 more
europepmc   +1 more source

Erratum to: Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid [PDF]

, 2014
Roger von Moos, Jean-Jacques Body, Blair Egerdie, Alison Stopeck, Janet E. Brown, Danail Damyanov, Lesley Fallowfield, Gavin Marx, Charles S. Cleeland, Donald L. Patrick, Felipe Palazzo, Yi Qian, Ada Braun, Karen Chung   +13 more
openalex   +1 more source

Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases. [PDF]

J Clin Med
Aliyev V, Guliyev M, Günaltılı M, Fidan MC, Çerme E, Abbasov H, Birsin Z, Cebeci S, Demirci NS, Alan Ö.   +9 more
europepmc   +1 more source

Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis. [PDF]

Breast Cancer Res Treat
Iwai C, Konishi T, Miyawaki A, Okada A, Isogai T, Jo T, Yasunaga H.   +6 more
europepmc   +1 more source